Učitavanje...
Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small molecular agents that target the tyrosine kinase domain of the EGFR, were approved in many countries for the treatm...
Spremljeno u:
| Glavni autori: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2012
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3244201/ https://ncbi.nlm.nih.gov/pubmed/22229045 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834011427927 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|